Dysplasia as a predictive marker for invasive carcinoma in barrett esophagus

A follow-up study based on 138 cases from a diagnostic variability study

Elizabeth Montgomery, John R. Goldblum, Joel K. Greenson, Marian M. Haber, Laura W. Lamps, Gregory Y. Lauwers, Audrey J Lazenby, David N. Lewin, Marie E. Robert, Kay Washington, Marianna L. Zahurak, John Hart

Research output: Contribution to journalArticle

235 Citations (Scopus)

Abstract

The objective of endoscopic surveillance in Barrett esophagus (BE) is to assess the risk of subsequent development of invasive carcinoma. Criteria for morphologic evaluation of dysplasia, the presumed precursor lesion, have been established, although there are surprisingly few data in the literature correlating biopsy diagnosis Of dysplasia with outcome. We collected follow-up information on 138 patients with BE whose initial endoscopic biopsy specimens had been selected for submission in an interobserver variability study performed by 12 pathologists with special interest in gastrointestinal pathology and reviewed blindly twice each by all the participants. Cases were scored as BE with no dysplasia, atypia indefinite for dysplasia (IND), low-grade dysplasia (LGD), high-grade dysplasia (HGD), intramucosal carcinoma, and frankly invasive carcinoma, thus generating 24 scores on each biopsy specimen. Clinical follow-up was obtained and correlated with both the submitting diagnoses and majority diagnoses. Kaplan-Meier statistics were used to compare both the submitting and majority diagnoses with outcome using detection or documentation of invasive carcinoma as the endpoint. Using the submitting diagnoses, no invasive carcinomas were detected in 44 cases diagnosed as BE (median follow-up, 38.5 months). Carcinomas were detected in 4 of 22 (18%) cases submitted as IND (median progression-free survival of 62 months), in 4 of 25 (15%) cases of LGD (median progression-free survival of 60 months), in 20 of 33 cases of HGD (median progression-free survival, 8 months), and all 13 (100%) cases submitted as adenocarcinoma. Grade on initial biopsy correlated significantly with progression to invasive carcinoma (log-rank P = .0001). Majority diagnosis was achieved in 99 of the cases. Using the majority diagnoses, no invasive carcinomas were found in 50 cases of BE (median follow-up, 48 months), and carcinomas were detected in 1 of 7 (14%) IND cases (80% progression-free survival at 2 months), 3 of 15 (20%) LGD (median progression-free survival, 60 months), 9 of 15 (60%) HGD (median progression-free survival, 7 months), and all 12 (100%) carcinoma. Initial grading again correlated significantly with progression to invasive carcinoma (log-rank P = .0001). However, there were 39 cases without a majority diagnosis. Among these, no carcinomas developed in 8 cases with an average score between BE and IND. Carcinomas were detected in 9 of 21 (43%) cases with an average score between IND and LGD, and 7 of 10 (70%) cases with an average score between LGD and HGD. There were ulcers in 8 of 39 cases (20%) of the "no-majority" group and in 13 of 99 (15%) of the majority cases. Of 21 total ulcerated cases, cancer was demonstrated in 15 (71%) of these on follow-up. These data support combining the IND and LGD categories for surveillance purposes. Cases without dysplasia may be followed up conservatively. The data obtained from submitted diagnoses as opposed to those from blind review suggest that knowledge of the clinical findings aids in diagnosis. The data also support the assertion that HGD is strongly associated with invasive carcinoma. Rebiopsy of ulcerated areas should be considered because they may harbor malignancy. Histologic grading of dysplasia using established criteria is a powerful prognosticator in BE.

Original languageEnglish (US)
Pages (from-to)379-388
Number of pages10
JournalHuman Pathology
Volume32
Issue number4
DOIs
StatePublished - Jan 1 2001

Fingerprint

Barrett Esophagus
Carcinoma
Disease-Free Survival
Biopsy
Observer Variation
Documentation
Ulcer
Neoplasms

Keywords

  • Barrett adenocarcinoma
  • Barrett esophagus
  • Dysplasia
  • Grading
  • Prognostic markers

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Dysplasia as a predictive marker for invasive carcinoma in barrett esophagus : A follow-up study based on 138 cases from a diagnostic variability study. / Montgomery, Elizabeth; Goldblum, John R.; Greenson, Joel K.; Haber, Marian M.; Lamps, Laura W.; Lauwers, Gregory Y.; Lazenby, Audrey J; Lewin, David N.; Robert, Marie E.; Washington, Kay; Zahurak, Marianna L.; Hart, John.

In: Human Pathology, Vol. 32, No. 4, 01.01.2001, p. 379-388.

Research output: Contribution to journalArticle

Montgomery, E, Goldblum, JR, Greenson, JK, Haber, MM, Lamps, LW, Lauwers, GY, Lazenby, AJ, Lewin, DN, Robert, ME, Washington, K, Zahurak, ML & Hart, J 2001, 'Dysplasia as a predictive marker for invasive carcinoma in barrett esophagus: A follow-up study based on 138 cases from a diagnostic variability study', Human Pathology, vol. 32, no. 4, pp. 379-388. https://doi.org/10.1053/hupa.2001.23511
Montgomery, Elizabeth ; Goldblum, John R. ; Greenson, Joel K. ; Haber, Marian M. ; Lamps, Laura W. ; Lauwers, Gregory Y. ; Lazenby, Audrey J ; Lewin, David N. ; Robert, Marie E. ; Washington, Kay ; Zahurak, Marianna L. ; Hart, John. / Dysplasia as a predictive marker for invasive carcinoma in barrett esophagus : A follow-up study based on 138 cases from a diagnostic variability study. In: Human Pathology. 2001 ; Vol. 32, No. 4. pp. 379-388.
@article{d6870ad29dcb42d48a4460489a1eed68,
title = "Dysplasia as a predictive marker for invasive carcinoma in barrett esophagus: A follow-up study based on 138 cases from a diagnostic variability study",
abstract = "The objective of endoscopic surveillance in Barrett esophagus (BE) is to assess the risk of subsequent development of invasive carcinoma. Criteria for morphologic evaluation of dysplasia, the presumed precursor lesion, have been established, although there are surprisingly few data in the literature correlating biopsy diagnosis Of dysplasia with outcome. We collected follow-up information on 138 patients with BE whose initial endoscopic biopsy specimens had been selected for submission in an interobserver variability study performed by 12 pathologists with special interest in gastrointestinal pathology and reviewed blindly twice each by all the participants. Cases were scored as BE with no dysplasia, atypia indefinite for dysplasia (IND), low-grade dysplasia (LGD), high-grade dysplasia (HGD), intramucosal carcinoma, and frankly invasive carcinoma, thus generating 24 scores on each biopsy specimen. Clinical follow-up was obtained and correlated with both the submitting diagnoses and majority diagnoses. Kaplan-Meier statistics were used to compare both the submitting and majority diagnoses with outcome using detection or documentation of invasive carcinoma as the endpoint. Using the submitting diagnoses, no invasive carcinomas were detected in 44 cases diagnosed as BE (median follow-up, 38.5 months). Carcinomas were detected in 4 of 22 (18{\%}) cases submitted as IND (median progression-free survival of 62 months), in 4 of 25 (15{\%}) cases of LGD (median progression-free survival of 60 months), in 20 of 33 cases of HGD (median progression-free survival, 8 months), and all 13 (100{\%}) cases submitted as adenocarcinoma. Grade on initial biopsy correlated significantly with progression to invasive carcinoma (log-rank P = .0001). Majority diagnosis was achieved in 99 of the cases. Using the majority diagnoses, no invasive carcinomas were found in 50 cases of BE (median follow-up, 48 months), and carcinomas were detected in 1 of 7 (14{\%}) IND cases (80{\%} progression-free survival at 2 months), 3 of 15 (20{\%}) LGD (median progression-free survival, 60 months), 9 of 15 (60{\%}) HGD (median progression-free survival, 7 months), and all 12 (100{\%}) carcinoma. Initial grading again correlated significantly with progression to invasive carcinoma (log-rank P = .0001). However, there were 39 cases without a majority diagnosis. Among these, no carcinomas developed in 8 cases with an average score between BE and IND. Carcinomas were detected in 9 of 21 (43{\%}) cases with an average score between IND and LGD, and 7 of 10 (70{\%}) cases with an average score between LGD and HGD. There were ulcers in 8 of 39 cases (20{\%}) of the {"}no-majority{"} group and in 13 of 99 (15{\%}) of the majority cases. Of 21 total ulcerated cases, cancer was demonstrated in 15 (71{\%}) of these on follow-up. These data support combining the IND and LGD categories for surveillance purposes. Cases without dysplasia may be followed up conservatively. The data obtained from submitted diagnoses as opposed to those from blind review suggest that knowledge of the clinical findings aids in diagnosis. The data also support the assertion that HGD is strongly associated with invasive carcinoma. Rebiopsy of ulcerated areas should be considered because they may harbor malignancy. Histologic grading of dysplasia using established criteria is a powerful prognosticator in BE.",
keywords = "Barrett adenocarcinoma, Barrett esophagus, Dysplasia, Grading, Prognostic markers",
author = "Elizabeth Montgomery and Goldblum, {John R.} and Greenson, {Joel K.} and Haber, {Marian M.} and Lamps, {Laura W.} and Lauwers, {Gregory Y.} and Lazenby, {Audrey J} and Lewin, {David N.} and Robert, {Marie E.} and Kay Washington and Zahurak, {Marianna L.} and John Hart",
year = "2001",
month = "1",
day = "1",
doi = "10.1053/hupa.2001.23511",
language = "English (US)",
volume = "32",
pages = "379--388",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Dysplasia as a predictive marker for invasive carcinoma in barrett esophagus

T2 - A follow-up study based on 138 cases from a diagnostic variability study

AU - Montgomery, Elizabeth

AU - Goldblum, John R.

AU - Greenson, Joel K.

AU - Haber, Marian M.

AU - Lamps, Laura W.

AU - Lauwers, Gregory Y.

AU - Lazenby, Audrey J

AU - Lewin, David N.

AU - Robert, Marie E.

AU - Washington, Kay

AU - Zahurak, Marianna L.

AU - Hart, John

PY - 2001/1/1

Y1 - 2001/1/1

N2 - The objective of endoscopic surveillance in Barrett esophagus (BE) is to assess the risk of subsequent development of invasive carcinoma. Criteria for morphologic evaluation of dysplasia, the presumed precursor lesion, have been established, although there are surprisingly few data in the literature correlating biopsy diagnosis Of dysplasia with outcome. We collected follow-up information on 138 patients with BE whose initial endoscopic biopsy specimens had been selected for submission in an interobserver variability study performed by 12 pathologists with special interest in gastrointestinal pathology and reviewed blindly twice each by all the participants. Cases were scored as BE with no dysplasia, atypia indefinite for dysplasia (IND), low-grade dysplasia (LGD), high-grade dysplasia (HGD), intramucosal carcinoma, and frankly invasive carcinoma, thus generating 24 scores on each biopsy specimen. Clinical follow-up was obtained and correlated with both the submitting diagnoses and majority diagnoses. Kaplan-Meier statistics were used to compare both the submitting and majority diagnoses with outcome using detection or documentation of invasive carcinoma as the endpoint. Using the submitting diagnoses, no invasive carcinomas were detected in 44 cases diagnosed as BE (median follow-up, 38.5 months). Carcinomas were detected in 4 of 22 (18%) cases submitted as IND (median progression-free survival of 62 months), in 4 of 25 (15%) cases of LGD (median progression-free survival of 60 months), in 20 of 33 cases of HGD (median progression-free survival, 8 months), and all 13 (100%) cases submitted as adenocarcinoma. Grade on initial biopsy correlated significantly with progression to invasive carcinoma (log-rank P = .0001). Majority diagnosis was achieved in 99 of the cases. Using the majority diagnoses, no invasive carcinomas were found in 50 cases of BE (median follow-up, 48 months), and carcinomas were detected in 1 of 7 (14%) IND cases (80% progression-free survival at 2 months), 3 of 15 (20%) LGD (median progression-free survival, 60 months), 9 of 15 (60%) HGD (median progression-free survival, 7 months), and all 12 (100%) carcinoma. Initial grading again correlated significantly with progression to invasive carcinoma (log-rank P = .0001). However, there were 39 cases without a majority diagnosis. Among these, no carcinomas developed in 8 cases with an average score between BE and IND. Carcinomas were detected in 9 of 21 (43%) cases with an average score between IND and LGD, and 7 of 10 (70%) cases with an average score between LGD and HGD. There were ulcers in 8 of 39 cases (20%) of the "no-majority" group and in 13 of 99 (15%) of the majority cases. Of 21 total ulcerated cases, cancer was demonstrated in 15 (71%) of these on follow-up. These data support combining the IND and LGD categories for surveillance purposes. Cases without dysplasia may be followed up conservatively. The data obtained from submitted diagnoses as opposed to those from blind review suggest that knowledge of the clinical findings aids in diagnosis. The data also support the assertion that HGD is strongly associated with invasive carcinoma. Rebiopsy of ulcerated areas should be considered because they may harbor malignancy. Histologic grading of dysplasia using established criteria is a powerful prognosticator in BE.

AB - The objective of endoscopic surveillance in Barrett esophagus (BE) is to assess the risk of subsequent development of invasive carcinoma. Criteria for morphologic evaluation of dysplasia, the presumed precursor lesion, have been established, although there are surprisingly few data in the literature correlating biopsy diagnosis Of dysplasia with outcome. We collected follow-up information on 138 patients with BE whose initial endoscopic biopsy specimens had been selected for submission in an interobserver variability study performed by 12 pathologists with special interest in gastrointestinal pathology and reviewed blindly twice each by all the participants. Cases were scored as BE with no dysplasia, atypia indefinite for dysplasia (IND), low-grade dysplasia (LGD), high-grade dysplasia (HGD), intramucosal carcinoma, and frankly invasive carcinoma, thus generating 24 scores on each biopsy specimen. Clinical follow-up was obtained and correlated with both the submitting diagnoses and majority diagnoses. Kaplan-Meier statistics were used to compare both the submitting and majority diagnoses with outcome using detection or documentation of invasive carcinoma as the endpoint. Using the submitting diagnoses, no invasive carcinomas were detected in 44 cases diagnosed as BE (median follow-up, 38.5 months). Carcinomas were detected in 4 of 22 (18%) cases submitted as IND (median progression-free survival of 62 months), in 4 of 25 (15%) cases of LGD (median progression-free survival of 60 months), in 20 of 33 cases of HGD (median progression-free survival, 8 months), and all 13 (100%) cases submitted as adenocarcinoma. Grade on initial biopsy correlated significantly with progression to invasive carcinoma (log-rank P = .0001). Majority diagnosis was achieved in 99 of the cases. Using the majority diagnoses, no invasive carcinomas were found in 50 cases of BE (median follow-up, 48 months), and carcinomas were detected in 1 of 7 (14%) IND cases (80% progression-free survival at 2 months), 3 of 15 (20%) LGD (median progression-free survival, 60 months), 9 of 15 (60%) HGD (median progression-free survival, 7 months), and all 12 (100%) carcinoma. Initial grading again correlated significantly with progression to invasive carcinoma (log-rank P = .0001). However, there were 39 cases without a majority diagnosis. Among these, no carcinomas developed in 8 cases with an average score between BE and IND. Carcinomas were detected in 9 of 21 (43%) cases with an average score between IND and LGD, and 7 of 10 (70%) cases with an average score between LGD and HGD. There were ulcers in 8 of 39 cases (20%) of the "no-majority" group and in 13 of 99 (15%) of the majority cases. Of 21 total ulcerated cases, cancer was demonstrated in 15 (71%) of these on follow-up. These data support combining the IND and LGD categories for surveillance purposes. Cases without dysplasia may be followed up conservatively. The data obtained from submitted diagnoses as opposed to those from blind review suggest that knowledge of the clinical findings aids in diagnosis. The data also support the assertion that HGD is strongly associated with invasive carcinoma. Rebiopsy of ulcerated areas should be considered because they may harbor malignancy. Histologic grading of dysplasia using established criteria is a powerful prognosticator in BE.

KW - Barrett adenocarcinoma

KW - Barrett esophagus

KW - Dysplasia

KW - Grading

KW - Prognostic markers

UR - http://www.scopus.com/inward/record.url?scp=0035034648&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035034648&partnerID=8YFLogxK

U2 - 10.1053/hupa.2001.23511

DO - 10.1053/hupa.2001.23511

M3 - Article

VL - 32

SP - 379

EP - 388

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

IS - 4

ER -